Beacon Pointe Advisors’s AbbVie ABBV Stock Holding History

Beacon Pointe Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,700	Closed	-$625K	–	1505
2025 Q3	$625K	Buy	+2,700	New	+$550K	0.01%	934

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Beacon Pointe Advisors's ABBV Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its AbbVie (ABBV) stake by 2.5% in Q2 2026, selling an estimated $1.06M and leaving 195,761 shares worth $49.3M. The position accounts for 0.23% of the portfolio, ranked #97.

Beacon Pointe Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Beacon Pointe Advisors held 195,761 shares of AbbVie worth $49.3M as of Q2 2026.
Beacon Pointe Advisors sold 4,930 AbbVie shares in Q2 2026, an estimated $1.06M.
AbbVie made up 0.23% of Beacon Pointe Advisors's portfolio in Q2 2026, its #97 holding.
Beacon Pointe Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.